Journal of Clinical Trials
Open Access

Designing of inhibitors for cancer phenotype: An experimental and computational approach

Joint Event on 7^th International Conference on Clinical Trials & 12^th World CADD & Drug Delivery Summit

September 24-26, 2018 | Chicago, USA

Navaneetha Nambigari and Praveen Bachawala

Osmania University, India
Spray: Tek, Inc., USA

Scientific Tracks Abstracts: J Clin Trials

Abstract :

Cancer is a major public health problem worldwide and is the second leading cause of death in the United States. The discovery and ontogenesis of small molecule inhibitors of cancer have been remodeled with technological innovation. The application of computational techniques has been quickly ratified by the scientists in the field of targeted drug designing. The pharmacokinetic parameters (ADME) are important for the designing as well as targeted delivery to the site of infection/disease. The highly expressed proteins phenotypes in cancer are targeted through signaling pathways, leading to gene expression. In the present study computer-aided drug designing techniques are used to design drugs and potential binding affinities to understand the pharmacokinetic aspects of the lead i.e., ADME. Successful case studies will be discussed to understand the target specificity and site specificity. Bioinformatic tools are used for refining the 3D structure of the target protein, validation of the active site, virtual screening carried out to identify the leads (inhibitors), and synthesis of leads, in vitro and in vivo studies.

Biography :